Rapport: Rutinebrug af CYP-test ved antipsykotisk behandling

14. Hedgecoe A. The Politics of Personalised Medicine: Pharmacogenetics in theClinic. Cambridge: Cambridge University Press; 2004.15. Sct. Hans Hospital. Instruks vedrørende Genetisk analyse af cytokrom P450 i kliniskpsykiatri. Den Lokale Lægemidelkomite, 1. januar 2006. København: H:S; 2006.16. De Sundhedsfaglige Råd i Psykiatri i Københavns Amt og H:S. Behandling afpatienter med debuterende psykose, med gentagne psykoser og med akutte psykotisketilstande, del 1. København: Københavns Amt & H:S; 2006.17. Blue Cross and Blue Shield Association,Technology Evaluation Center. SpecialReport: Genotyping for Cytocrome P450 Polymorfisms to Determine DrugMetabolizer Status. Chicago, Ill.: Blue Cross Blue Shield Association; 2004.18. Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, et al. The clinicaleffectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms inpatients with schizophrenia treated with antipsychotics: a systematic review and economicevaluation. Health Technol Assess 2010 Jan;14(3):1-157, iii.19. Jurgens G, Jacobsen CB, Rasmussen HB, Werge T, Nordentoft M, Andersen SE.Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation intopsychiatric clinical practice. Acta Psychiatr Scand 2012 Mar;125(3):228-237.20. Jurgens G, Rasmussen HB, Werge T, Dalhoff K, Nordentoft M, Andersen SE.Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoseswithin the schizophrenic spectrum? J Clin Psychopharmacol 2012 Feb;32(1):100-105.21. Jurgens G, Rasmussen HB, Werge T, Dalhoff K, Nordentoft M, Andersen SE.Impact of Cytochrome P450 2D6 genotyping on the prescription of antipsychoticdrugs in patients diagnosed within the schizophrenic spectrum. A retrospective longitudinalstudy. Unpublished Unpublished.22. van der WJ, Steijns LS. Cytochrome P450 enzyme system: genetic polymorphismsand impact on clinical pharmacology. Ann Clin Biochem 1999 11;36 ( Pt 6):722-729.23. Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow J, Lau J, et al. Genetictest evaluation: information needs of clinicians, policy makers, and the public. Am JEpidemiol 2002 Aug 15;156(4):311-318.24. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. NonfunctionalCYP2D6 alleles and risk for neuroleptic-induced movement disorders inschizophrenic patients. Psychopharmacology (Berl) 1997 05;131(2):174-179.25. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic druginducedmovement disorders in schizophrenics in relation to CYP2D6 genotype. Br JPsychiatry 1997 01;170:23-26.26. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, et al. The impact of the CYP2D6 polymorphism on haloperidolpharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther2002 10;72(4):438-452.89 Rutinebrug af CYP-test ved antipsykotisk behandling